AU1688599A — Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
Assigned to Eisai Co Ltd · Expires 1999-07-26 · 27y expired
What this patent protects
The present invention relates to the use of A2 receptor antagonists and their pharmacologically acceptable salts or hydrates for preparing medicaments for preventing or treating diabetes mellitus or diabetic complications, and for preparing improving agents for impaired glucose t…
USPTO Abstract
The present invention relates to the use of A2 receptor antagonists and their pharmacologically acceptable salts or hydrates for preparing medicaments for preventing or treating diabetes mellitus or diabetic complications, and for preparing improving agents for impaired glucose tolerance, potentiating agent for insulin sensitivity or medicaments for preventing or treating obesity.
Drugs covered by this patent
- Nourianz (ISTRADEFYLLINE) · Kyowa Kirin
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.